Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Clinical Cardiology Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Glob Heart. 2023 Apr 20;18(1):19. doi: 10.5334/gh.1196. eCollection 2023.
Women are underrepresented in acute myocardial infarction (AMI) studies. Furthermore, there is scarce information regarding women with AMI in Latin America.
To describe the presentation, clinical characteristics, risk factor burden, evidence-based care, and in-hospital outcome in a population of women with AMI admitted to a coronary care unit (CCU) in Mexico.
Retrospective cohort study including patients with AMI admitted from January 2006 to December 2021 in a CCU. We identified patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). We described demographic characteristics, clinical variables, treatment, and in-hospital outcomes according to gender. Cox regression analysis was used to identify predictors of mortality.
Our study included 12,069 patients with AMI, of whom 7,599 had STEMI and 4,470 had NSTEMI. Women represented 19.6% of the population. Women had higher rates of hypertension, diabetes, stroke, and atrial fibrillation than men. For STEMI, women were less likely to receive reperfusion therapy (fibrinolysis; 23.7 vs. 28.5%, p < 0.001 and primary percutaneous coronary intervention (PCI); 31.2 vs. 35.1%, p = 0.001) and had more major adverse events than men: heart failure (4.2 vs. 2.5%, p = 0.002), pulmonary edema (3.4% vs. 1.7%, p < 0.001), major bleeding (2.1% vs. 1%, p = 0.002), stroke (1.3% vs. 0.6%, p = 0.008), and mortality (15.1% vs. 8.1%, p < 0.001). For NSTEMI, women were less likely to undergo coronary angiography or PCI and had more major bleeding and mortality. Multivariate Cox regression analysis revealed that females had an increase in mortality in STEMI and NSTEMI (HR 1.21, CI 1.01-1.47, p = 0.05 and HR 1.39, CI 1.06-1.81, p = 0.01).
Real-world evidence from a hospital in a Latin American low- to middle-income country (LMIC) showed that women with AMI had more comorbidities, received less reperfusion treatment or invasive strategies, and had worse outcomes. In STEMI and NSTEMI, female gender represented an independent predictor of in-hospital mortality.
在急性心肌梗死(AMI)研究中,女性代表性不足。此外,关于拉丁美洲女性 AMI 的信息很少。
描述墨西哥冠心病监护病房(CCU)收治的 AMI 女性患者的临床表现、临床特征、危险因素负担、循证治疗和住院结局。
这是一项回顾性队列研究,纳入了 2006 年 1 月至 2021 年 12 月在 CCU 收治的 AMI 患者。我们确定了 ST 段抬高型心肌梗死(STEMI)和非 ST 段抬高型心肌梗死(NSTEMI)患者。我们根据性别描述了人口统计学特征、临床变量、治疗和住院结局。使用 Cox 回归分析确定死亡率的预测因素。
我们的研究纳入了 12069 例 AMI 患者,其中 7599 例为 STEMI,4470 例为 NSTEMI。女性占患者总数的 19.6%。与男性相比,女性高血压、糖尿病、卒中和心房颤动的发生率更高。对于 STEMI,女性接受再灌注治疗(纤溶酶原激活物;23.7%比 28.5%,p<0.001 和经皮冠状动脉介入治疗(PCI);31.2%比 35.1%,p=0.001)的可能性较小,并且比男性发生更多的主要不良事件:心力衰竭(4.2%比 2.5%,p=0.002)、肺水肿(3.4%比 1.7%,p<0.001)、大出血(2.1%比 1%,p=0.002)、卒中和死亡率(1.3%比 0.6%,p=0.008)。对于 NSTEMI,女性接受冠状动脉造影或 PCI 的可能性较小,并且大出血和死亡率较高。多变量 Cox 回归分析显示,女性 STEMI 和 NSTEMI 的死亡率增加(HR 1.21,CI 1.01-1.47,p=0.05 和 HR 1.39,CI 1.06-1.81,p=0.01)。
来自拉丁美洲中低收入国家(LMIC)一家医院的真实世界证据表明,AMI 女性患者合并症更多,接受再灌注治疗或有创策略的可能性较小,且结局更差。在 STEMI 和 NSTEMI 中,女性是住院死亡率的独立预测因素。